Novartis to acquire Regulus for $7.00 a share in cash

TBE/iStock Editorial via Getty Images Novartis ( NYSE: NVS ) has agreed to acquire biopharmaceutical firm Regulus Therapeutics ( NASDAQ: RGLS ) for an initial payment of $7.00 a share in cash at closing, or $0.8B.

The upfront cash portion of the consideration represents a premium of 108% to Regulus' closing price on.